A reduced omalizumab response may be associated with persistent eosinophilic inflammation. Other antieosinophilic treatments should be considered for such patients.
Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes
Scalese Marco;
2019
Abstract
A reduced omalizumab response may be associated with persistent eosinophilic inflammation. Other antieosinophilic treatments should be considered for such patients.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
68_Higher blood eosinophil levels may be associated with poorer asthma.pdf
solo utenti autorizzati
Descrizione: Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes
Tipologia:
Versione Editoriale (PDF)
Licenza:
Altro tipo di licenza
Dimensione
338.09 kB
Formato
Adobe PDF
|
338.09 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
